Tom A Fuchs
Overview
Explore the profile of Tom A Fuchs including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
280
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ziccardi S, Guandalini M, Fuchs T, Calabrese M, Benedict R
Mult Scler
. 2024 Aug;
30(11-12):1402-1404.
PMID: 39193704
Progression independent of relapse activity (PIRA) has been recently proposed in multiple sclerosis (MS) as a model identifying a continuous silent progression of disability without the manifestation of new clinical...
2.
Fuchs T, Schoonheim M, Zivadinov R, Dwyer M, Colato E, Weinstock Z, et al.
Mult Scler
. 2024 Aug;
30(11-12):1468-1478.
PMID: 39193699
Background: Substantial physical-disability worsening in relapsing-remitting multiple sclerosis (RRMS) occurs outside of clinically recorded relapse. This phenomenon, termed progression independent of relapse activity (PIRA), is yet to be established for...
3.
Fuchs T, Zivadinov R, Pryshchepova T, Weinstock-Guttman B, Dwyer M, Benedict R, et al.
Mult Scler Relat Disord
. 2024 Jul;
89:105755.
PMID: 39018643
Background: Because secondary progressive multiple sclerosis (SPMS) is associated with worse prognosis, early predictive tools are needed. We aimed to use systematic literature review and advanced methods to create and...
4.
Zivadinov R, Bergsland N, Jakimovski D, Weinstock-Guttman B, Lorefice L, Schoonheim M, et al.
Neuroimage Clin
. 2024 May;
42:103609.
PMID: 38718640
Background: Prior research has established a link between thalamic pathology and cognitive impairment (CI) in people with multiple sclerosis (pwMS). However, the translation of these findings to pwMS in everyday...
5.
van Dam M, Krijnen E, Nauta I, Fuchs T, de Jong B, Klein M, et al.
J Neurol
. 2024 Feb;
271(5):2195-2206.
PMID: 38409536
Background: The heterogeneous nature of cognitive impairment in people with multiple sclerosis (PwMS) hampers understanding of the underlying mechanisms and developing patient-tailored interventions. We aim to identify and classify cognitive...
6.
Jakimovski D, Zivadinov R, Weinstock Z, Fuchs T, Bartnik A, Dwyer M, et al.
J Neurol
. 2023 Aug;
270(11):5223-5234.
PMID: 37634161
Background: The structural changes associated with cognitive performance in older people with multiple sclerosis (PwMS; age ≥ 50 years old) remain unknown. Objective: To determine the relationship between whole-brain (WBV),...
7.
Motyl J, Friedova L, Ganapathy Subramanian R, Vaneckova M, Fuchs T, Krasensky J, et al.
Acta Neurol Belg
. 2023 Aug;
124(1):109-118.
PMID: 37552396
Background: Although there is evidence that shows worse cognitive functioning in male patients with multiple sclerosis (MS), the role of brain pathology in this context is under-investigated. Objective: To investigate...
8.
Functional alteration due to structural damage is network dependent: insight from multiple sclerosis
Bartnik A, Fuchs T, Ashton K, Kuceyeski A, Li X, Mallory M, et al.
Cereb Cortex
. 2022 Dec;
33(10):6090-6102.
PMID: 36585775
Little is known about how the brain's functional organization changes over time with respect to structural damage. Using multiple sclerosis as a model of structural damage, we assessed how much...
9.
Fuchs T, Gillies J, Jaworski 3rd M, Wilding G, Youngs M, Weinstock-Guttman B, et al.
Mult Scler Relat Disord
. 2022 Dec;
68:104375.
PMID: 36544304
Background: The Symbol Digit Modalities Test (SDMT), the most reliable and sensitive measure of cognition in people with multiple sclerosis (PwMS), is increasingly used in clinical trials and care. Objectives:...
10.
Fuchs T, Wattengel B, Carter M, El-Solh A, Lesse A, Mergenhagen K
Mult Scler Relat Disord
. 2022 Jun;
64:103964.
PMID: 35724529
Background: Given concerns over immune function, the decision whether to continue disease modifying therapy (DMT) in multiple sclerosis (MS) patients during the COVID-19 pandemic has been challenging, complicated by the...